News Related to ESCC

Related coverage linked through entity extraction aliases.

CStone's CS2009 Trispecific Antibody Receives FDA Clearance for Phase II Trial

Feb 16, 2026

CStone Pharmaceuticals received FDA IND clearance to initiate a Phase II trial of CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors across nine cancer indications.

CStone Pharmaceuticals Receives FDA Clearance for CS2009 Phase II Trial in Advanced Solid Tumors

Feb 16, 2026

CStone Pharmaceuticals received FDA IND clearance to begin a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGF, and CTLA-4, in advanced solid tumors across nine cancer indications.